Glenmark bond: the right medicine for Indian HY?

Generic drug manufacturer takes advantage of rising order books for Indian high-yield deals to price significantly through many brokers' fair value estimates.

Generic drug manufacturer Glenmark Pharmaceuticals executed a debut $200 million bond issue on Monday, taking advantage of rising demand for Indian high-yield deals to price significantly through brokers' fair value estimates. 

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media